Search Results

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the “Study”).

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce further positive interim results from its study

The Breast Cancer Society of Canada announced $250,000 in funding to the Department of Biochemistry and Molecular Biology, Faculty of Medicine at Dalhousie University, for a research project led by Dr. Paola Marignani.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) announces further results from the triple negative breast cancer murine model portion of its current research study at Dalhousie University (the “Study”) which confirms that the previously reported tumor volume reduction was due to activation of a tumor specific systemic immune response.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

ELEVAI LABS, INC. is pleased to report a stem cell exosome research partnership with Dr. Stanislav Sokolenko’s Lab at Dalhousie University and a non-repayable Grant from the Mitacs Accelerate Grants Program.